<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8F0283C3-00D9-4A8D-84A0-BD263351673A"><gtr:id>8F0283C3-00D9-4A8D-84A0-BD263351673A</gtr:id><gtr:name>Chris Hani Baragwanath Hospital, Johannesburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/25C60384-2198-49A1-AB36-A119CB488BE0"><gtr:id>25C60384-2198-49A1-AB36-A119CB488BE0</gtr:id><gtr:name>Canadian Institutes of Health Research (CIHR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2CE74112-EE4A-4FF7-A497-113512458D39"><gtr:id>2CE74112-EE4A-4FF7-A497-113512458D39</gtr:id><gtr:name>Dow University of Health Sciences, Pakistan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D823EA07-1051-4A9C-825E-302E9C864B07"><gtr:id>D823EA07-1051-4A9C-825E-302E9C864B07</gtr:id><gtr:name>RDECOM (Research Development and Engineering Command US Army Chemical and Biological centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8F0283C3-00D9-4A8D-84A0-BD263351673A"><gtr:id>8F0283C3-00D9-4A8D-84A0-BD263351673A</gtr:id><gtr:name>Chris Hani Baragwanath Hospital, Johannesburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/25C60384-2198-49A1-AB36-A119CB488BE0"><gtr:id>25C60384-2198-49A1-AB36-A119CB488BE0</gtr:id><gtr:name>Canadian Institutes of Health Research (CIHR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2CE74112-EE4A-4FF7-A497-113512458D39"><gtr:id>2CE74112-EE4A-4FF7-A497-113512458D39</gtr:id><gtr:name>Dow University of Health Sciences, Pakistan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D823EA07-1051-4A9C-825E-302E9C864B07"><gtr:id>D823EA07-1051-4A9C-825E-302E9C864B07</gtr:id><gtr:name>RDECOM (Research Development and Engineering Command US Army Chemical and Biological centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/58CEB547-5D69-4DCF-8BFB-56A641550212"><gtr:id>58CEB547-5D69-4DCF-8BFB-56A641550212</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Walsh</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F67A437C-57EE-4A28-9451-74BDF8593ACC"><gtr:id>F67A437C-57EE-4A28-9451-74BDF8593ACC</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Spencer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/938311FB-2998-4FA4-B30A-447B6572B1C0"><gtr:id>938311FB-2998-4FA4-B30A-447B6572B1C0</gtr:id><gtr:firstName>Christopher Joseph</gtr:firstName><gtr:surname>Schofield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3E1AE217-F31D-47CB-9DA4-DBD955AF4D48"><gtr:id>3E1AE217-F31D-47CB-9DA4-DBD955AF4D48</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Fishwick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/02B6EA93-8FE6-4544-B992-7B00CFFF0A78"><gtr:id>02B6EA93-8FE6-4544-B992-7B00CFFF0A78</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>Toleman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100135"><gtr:id>207C1E49-5A4F-4BA4-891E-1E873DE2229C</gtr:id><gtr:title>Combatting the threat of carbapenem resistance in Gram-negative bacterial pathogens</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100135</gtr:grantReference><gtr:abstractText>Hospital-acquired infections (HAIs) are growing in importance as the numbers of susceptible individuals (e.g. elderly, transplant or cancer chemotherapy patients) increase in aging populations. HAIs caused by antibiotic-resistant bacteria are more difficult to treat and consequently more dangerous. While MRSA (methicillin-resistant Staphylococcus aureus) is the most notorious cause of HAIs, so-called Gram-negative bacteria, such as Escherichia coli, are also responsible for many thousands of HAIs each year. The most important antibiotics in the fight against HAIs caused by these organisms are the beta-lactam drugs, of which penicillin is the best known. Since Gram-negative bacteria have become resistant to most other antibiotics, drugs called carbapenems (the most powerful beta-lactams) are now the most important antibiotics used to treat these infections. Fortunately, until recently carbapenem resistance in Gram-negative bacteria has been relatively rare, and usually encountered in bacteria that cause fewer HAIs than E. coli and its relatives. However, this situation has now changed with the recent discovery that carbapenem-resistant strains of several Gram-negative bacteria (carrying a gene called NDM-1) are spreading rapidly worldwide. This is a significant concern because, while several new antibiotics are effective against MRSA, there are as yet no new drugs for antibiotic-resistant Gram-negative bacteria. Infections by carbapenem-resistant bacteria are consequently very hard to treat.
We aim to develop a new treatment for HAIs caused by carbapenem-resistant Gram-negative bacteria. Penicillin-resistant Gram-negative bacteria can be treated by combining penicillin with a drug that blocks the mechanism of resistance. However, it has not yet proved possible to block the activity of NDM-1 (or that of related genes). Our team, which combines chemists, biochemists and university and hospital microbiologists from the U.K. and Canada, will design, make and test molecules than block the function of carbapenem-resistance mechanisms like NDM-1 and that consequently will restore the ability of carbapenems to kill resistant Gram-negative bacteria. An antibiotic that is reliably active against these organisms will transform the outlook for many patients with HAIs. As part of this work we will also monitor the spread, particularly in hospitals, of bacteria that carry NDM-1 and similar genes, and identify the most important types to use in our testing programme. We will further develop new methods to test whether particular molecules are able to block the function of NDM-1. New methods and resources for testing how to block NDM-1 will also benefit efforts in the wider scientific community to overcome the threat of carbapenem-resistant HAIs.</gtr:abstractText><gtr:technicalSummary>Hospital acquired (nosocomial) infections are a growing threat to global public health. Opportunist Gram-negative bacterial pathogens, both the Enterobacteriaceae and non-fermenters such as Pseudomonas aeruginosa or Acinetobacter baumannii, cause a wide variety of such conditions. Carbapenems are increasingly becoming first choice treatments for infections by these organisms, but resistant strains, in particular those carrying various metallo-beta-lactamases (MBLs) are now proliferating. Notably, the NDM-1 MBL is rapidly disseminating in the Enterobacteriaceae on a global scale. No new antibiotics with anti-Gram-negative activity are at or close to the clinic, and MBLs resist the activity of all available beta-lactamase inhibitors. We propose to develop new inhibitors of the most clinically important MBLs that are suitable for progress towards clinical trials as combinations with existing carbapenems. We will identify inhibitors by a combination of in structure-based discovery, use of focussed libraries and optimisation of existing molecules; and develop and use new assays with which to test inhibition of MBLs in vitro. We will test their ability to restore carbapenem activity against clinically relevant MBL-producing strains identified by a programme of resistance monitoring, and optimise identified hits by repeated rounds of synthesis and screening that are guided by structural and biophysical studies. We will demonstrate the suitability of MBL inhibitors for further development using in vitro pharmacokinetic/pharmacodynamic models and toxicity tests. An MBL inhibitor of clinical use will transform the outlook for patients with Gram-negative infections, and the tools that we develop will also aid the efforts of the wider community towards this goal.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>999971</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>RDECOM (Research Development and Engineering Command US Army Chemical and Biological centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Whole genome sequencing and sequence analysis of 12 NDM-1 harbouring enteric bacteria (Walsh; Toleman)</gtr:description><gtr:id>6010EC42-26B9-4A1F-BCBF-2B3CE7B703FA</gtr:id><gtr:impact>Oral Presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2012 in San Francisco.</gtr:impact><gtr:partnerContribution>All sequencing performed and ~10% of the sequence analysis.</gtr:partnerContribution><gtr:piContribution>Timothy Walsh and Mark Toleman at Cardiff supplied strains to be sequenced. The US Army have performed all the sequencing. Sequence analysis, plasmid analysis and plasmid construction performed mostly by Dr Mark Toleman in Cardiff.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genomic sequencing of NDM-1 positive Acinetobacter spp.</gtr:description><gtr:id>8BB01B9A-DBDF-4911-B343-9081F7920F17</gtr:id><gtr:impact>ECCMID 2013 abstract. &amp;quot;A broad host range conjugative plasmid carrying blaNDM-1 in an Acinetobacter bereziniae isolate from India: Complete sequence and comparison with related genetic contexts&amp;quot;</gtr:impact><gtr:partnerContribution>Know how on sequencing etc</gtr:partnerContribution><gtr:piContribution>Initiated and established exchange of strains, data and ideas</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genomic sequencing of Russian ST235 with VIM-2</gtr:description><gtr:id>F8F8A2FE-AE5D-4ECA-A18E-E7A5BFC69D8C</gtr:id><gtr:impact>None thus far</gtr:impact><gtr:partnerContribution>Sequencing and annotation of sequences</gtr:partnerContribution><gtr:piContribution>Initated and established partnership. Preparation of DNA</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chris Hani Baragwanath Hospital, Johannesburg</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Medical Microbiology</gtr:department><gtr:description>Carriage of carbapenem resistant bacteria in Johannesburg and Sowetto</gtr:description><gtr:id>8177D202-7F4E-44C0-BA4F-6C05CBBE1AF0</gtr:id><gtr:impact>None so far</gtr:impact><gtr:partnerContribution>Collecting and sending of specimens</gtr:partnerContribution><gtr:piContribution>Initiated collaboration and will undertake molecular biology</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genomic sequencing of NDM-1 positive V. cholerae</gtr:description><gtr:id>F5074A3C-576B-480B-97AC-FB51FCAF942F</gtr:id><gtr:impact>ECCMID 2012. The genetic context of blaNDM-1 in Vibrio cholerae</gtr:impact><gtr:partnerContribution>Initiated and established the collaboration</gtr:partnerContribution><gtr:piContribution>Initiated and established the collaboration</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dow University of Health Sciences, Pakistan</gtr:collaboratingOrganisation><gtr:country>Pakistan, Islamic Republic of</gtr:country><gtr:department>Dow Medical College</gtr:department><gtr:description>Carraige and infection rates with NDM-1 positive bacteria in Pakistan</gtr:description><gtr:id>F0FAABD9-EBE7-4BA6-8B4D-9A98423A80F6</gtr:id><gtr:impact>ECCMID 2013 abstract &amp;quot;Frequency of carriage of NDM-1 and CTX-M-15 among patients from hospitals in Karachi: preliminary data assessing risk factors for carriage and infection&amp;quot;</gtr:impact><gtr:partnerContribution>Training nurses, data collection, transporting specimens</gtr:partnerContribution><gtr:piContribution>Initiated, established and funded field work in Karachi plus transport</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Institutes of Health Research (CIHR)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>MRC CIHR Team grant</gtr:description><gtr:id>EB578193-4B39-4840-8193-B7CDCC32267B</gtr:id><gtr:impact>As this is a co-funded proposal all listed outputs result from the partnership described.</gtr:impact><gtr:partnerContribution>Canada team provides complementary expertise in Clinical Microbiology (Pillai); Structural Biology (Strynadka); Inorganic Biochemistry (Siemann); Synthetic and Medicinal Chemistry (Dmitrienko, Lubell, Liu)</gtr:partnerContribution><gtr:piContribution>UK team provides expertise in Clinical Microbiology (Walsh; Toleman); Structural Biology and Biochemistry (Spencer); in silico Drug Discovery (Fishwick) and ChemicalBiology (Schofield)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview for Daily Telegraph online feature (Walsh)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>93306B50-F419-47E1-B91B-FC8EA6A6858A</gtr:id><gtr:impact>Interview formed part of a extensive online article on antimicrobial resistance

The item has been extensively shared on social media- Twitter, Facebook etc.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://s.telegraph.co.uk/graphics/projects/antibiotic-resistance/index.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium talk: &quot;Do beta-lactams have a future?&quot; (Walsh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B90BA40-915C-437A-8AF3-1CE4A1F6E87A</gtr:id><gtr:impact>Professor Walsh was an invited speaker at this symposium organised to mark the award of an ACS Citation for Chemical Breakthrough to Oxford University on recognition of their role in the development of penicillin</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science: Oxford Oxygen Stories - from penicillin to hypoxia sensing (Schofield)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>02339911-9DA7-4D40-9A06-97CF9AD91FB3</gtr:id><gtr:impact>Talk for general public as part of the 2013 Pint of Science Festival sparked questions and discussion afterwards.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.oxfordscibar.com/podcast.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture, St. Olave's School (Spencer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A62017EC-DCB3-4CE0-A4A2-1E6FD6268DFA</gtr:id><gtr:impact>Extensive formal and informal Q&amp;amp;A afterwards with audience members

Subsequent invitation to another schools event organised by the Royal Society of Chemistry</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.saintolaves.net/uploads/ckeditor/attachments/273/The_Olavian_Lecture_Series_II.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Bodmin College; Spencer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D4C71985-9DA3-46C4-923F-3EBBD56F61A8</gtr:id><gtr:impact>I talked to c. 120 yr 10 and yr 11 students as a part of a half day ChemNet event organised by the Royal Society of Chemistry. This generated questions and discussion with positive feedback from students and staff, and reported increased interest in the subject area.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.rsc.org/events/detail/17252/look-what-chemistry-has-done-for-me</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ITV tonight (Walsh)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>02BE4A46-1AFF-44FE-A3DE-27F3CECAE2B1</gtr:id><gtr:impact>This special report (October 24th 2013) featured Prof. Walsh sampling river water in India as part of an investigation into the distribution and prevalance of the NDM-1 carbapenemase.

.Broadening public awareness of global issues on extreme antibiotic resistance.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.itv.com/news/2013-10-24/tonight-when-the-drugs-dont-work/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote speaker at the 2012 13th APCCMI Congress, Beijing (Walsh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DD00ED6-64E5-443A-AD08-3B58D9DC9F2A</gtr:id><gtr:impact>Invited key note speaker on the risk factors for emergence and dissemination of carbapenem resistant bacteria.
http://www.apccmi2012.org/index.html

undefined</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Horizon (Walsh)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C02827FC-45DD-454C-B31B-3B1F993BC549</gtr:id><gtr:impact>BBC Horizon (October 2012) covered our collaborations with the Civil hospital in Karachi and how we are trying determine the global levels of carbapenem resistant bacteria.

Broadening public awareness of global issues on extreme antibiotic resistance.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b01ms5c6</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Back from the Dead Exhibition, History of Science Museum, Oxford (http://www.mhs.ox.ac.uk/backfromthedead/)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CA83D53A-7A1A-4FD6-A56F-55BE72CE514D</gtr:id><gtr:impact>Professor Schofield was scientific advisor to the &amp;quot;Back from the Dead&amp;quot; exhibition at the Oxford Museum of the History of Science charting the development of penicillin as a clinically useful drug.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.mhs.ox.ac.uk/backfromthedead/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Collaborating with developing Countries (Walsh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F91432C-798D-498C-B5A2-526F0DD8992A</gtr:id><gtr:impact>2000 people listened to the talk given at the 2012 IDSA, San Diego. 18/10/2012
http://www.idweek.org/

Undefined</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ABC TV interview (Walsh)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>187A7E2B-52EB-415E-935A-04545FA11B0A</gtr:id><gtr:impact>The presentation raised Australian public awareness of issues around antibiotic resistance in environmental and veterinary contexts.

The item sparked public debate on social media and was picked up by other media outlets both in Australia (eg http://www.foodmag.com.au/news/antibiotic-resistant-superbugs-could-spread-throug) and the US (http://www.krwa.net/newsDB/MainAnnounce2.asp?key=782)</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.abc.net.au/7.30/content/2013/s3810324.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Southville Primary School as part of Literacy Week (Bristol; Spencer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D0F46766-F286-409A-94F2-EEF4067E9E0B</gtr:id><gtr:impact>Talk generated extensive questioning on all aspects from science from a class of 7 year olds

Teacher reported continuing high levels of interest in science from that year group.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society of Chemistry panel meeting: Beating the Superbugs: avoiding an antibiotic apocalypse (Schofield; November 2013)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BBB32B3F-00B3-4B38-85A2-B1DE9A24CD0A</gtr:id><gtr:impact>Royal Society of Chemistry meeting: &amp;quot;Beating the Superbugs: avoiding an antibiotic apocalypse&amp;quot;
18 November 2013
The Chemistry Centre, Burlington House, Piccadilly, London W1J 0BA

Event is yet to take place.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.rsc.org/conferencesandevents/rscevents/chemistry-centre/antibiotic-apocalypse.asp</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium talk: &quot;Do beta-lactams have a future?&quot; (Spencer)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>19F57196-8EB5-4840-B037-FFD514110230</gtr:id><gtr:impact>Dr. Spencer was an invited speaker at a symposium organised to mark the award of an ACS Citation for Chemical Breakthrough to the University of Oxford in recognition of their work on the development of penicillin.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>137500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Studentship (Fishwick)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Biota?Pharmaceuticals</gtr:fundingOrg><gtr:id>4724ACC2-FCFB-43F0-ABBD-D9A4F98A9345</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI European Lead Factory (Schofield)</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>268C9A62-2002-4EC5-B724-073A5F31A93D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI New Drugs for Bad Bugs (Walsh)</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>ENABLE consortium</gtr:fundingRef><gtr:id>668F095A-1FE1-4873-B128-D8BD5DCE1CE4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>596080</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:department><gtr:description>Research Project Grant RO1 (Spencer)</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>1R01AI100560-01</gtr:fundingRef><gtr:id>7A7FE2DF-A995-4A7B-BB93-6A210F858BA0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>592169</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bridging the Gaps between the Engineering and Physical Sciences and Antimicrobial Resistance (Spencer, Co-I)</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/M027546/1	</gtr:fundingRef><gtr:id>676F0799-551C-4D1E-9FF4-770DC6C6BF80</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Screening of patients for carbapenemase positive bacteria in South Africa (Walsh)</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>66E278AB-7B01-4445-BF4E-236D365AF143</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>French Guidelines of screening patients for carbapenemases (Walsh)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>6BFF3005-17DD-4542-AD3E-D2EA5229276C</gtr:id><gtr:impact>France now regularly screening high-risk patients prior to admission in all French hospitals.</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Author Go Science Foresight positioning paper on antimicrobial resistance (Walsh)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>48974A14-5C39-4A63-9BBF-19A78AFF5263</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisory Board: EU Joint Programming Initiative on Antimicrobial Resistance (Walsh)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D090313D-2F94-4F94-A5F4-58BB202B50FC</gtr:id><gtr:impact>JPIAMR has developed a strategic research agenda (SRA) which is supported by the initiative's member states and other international players and has so far been realised in the first of a series of funding calls.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.jpiamr.eu/organisation/scentific-advisory-board/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New Antibiotics Initiative -IMI (Walsh)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>116A1ACA-1F0D-46CC-BFEB-6E88DFBFF8C4</gtr:id><gtr:impact>European scientific advisory board representative for the IMI to establish a clinical trial network throughout Europe to facilitate the rapid evaluation of new /novel antibiotics.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair, BBSRC Research Committee D (Schofield)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>35C07B36-B02A-4025-9884-9565847F333B</gtr:id><gtr:impact>The BBSRC invests in world-class bioscience research and training on behalf of the UK public. Research Committee D has a portfolio spanning &amp;quot;Molecules, cells and industrial biotechnology&amp;quot; and is responsible for dispensing, and assessing the impact of, public research funding in these areas as well as providing advice to policymakers.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.bbsrc.ac.uk/organisation/structures/committees/committee-d.aspx</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, International Scientific Advisory Board, CHARLI project</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>70876C27-E1D7-45DE-8F41-48C2BE4668ED</gtr:id><gtr:impact>This multicenter investigation will allow a homogenous collection of data and fulfill the need of improving international knowledge on multi-resistant bacteria infections in young children from low-income countries.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.charliproject.org/home.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>World Health Assembly (Walsh)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>246B2FA4-C19F-45B8-A33C-10618B084397</gtr:id><gtr:impact>Positioning paper presented at the World Health Assembly Congress in June 2012 to re-establish the importance of sewerage treatment in containing antibiotic resistance. A resolution on antimicrobial resistance was adopted at the 2014 World Health Assembly.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.euro.who.int/en/about-us/governance/regional-committee-for-europe/news/news/2014/05/world-health-assembly-closes-resolution-on-antimicrobial-resistance-approved</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Treatment of potable water in India (Walsh)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>818CE608-0A89-4631-A69D-64C28957B377</gtr:id><gtr:impact>Although not yet proven, distribution of chlorine tablets by the Indian government in response to the findings of our research in India has appeared to affect the number of patients presenting with D&amp;amp;V in the Delhi area.</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisor to WHO on global resistance and resistance mapping. Report released Jan 2014 (Walsh)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>88912DA2-0765-4AB0-B3A6-7F8BFF85E6C3</gtr:id><gtr:impact>Following this report the WHO has set up a Strategic and Technical Advisory Group (STAG) on antimicrobial resistance and is in the process of developing a Global Action Plan. See http://www.who.int/drugresistance/en/</gtr:impact><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.who.int/drugresistance/documents/surveillancereport/en/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Department of Health guidelines on detecting carbapenemases (Walsh)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B5F6F8B-78C3-4426-9CA3-7FC6CE19D846</gtr:id><gtr:impact>Proposed UK guidelines for screening admitted patients for carbapenemase-positive bacteria. As of 2014 the UK has implemented a Standard for Microbiological Investigation (SMI) for detection of carbapenemase-producing organisms.</gtr:impact><gtr:type>Participation in a national consultation</gtr:type><gtr:url>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/344071/P_8i1.1.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Chromo- and fluorigenic beta-lactams were synthesised and used as assays for beta-lactamase inhibitor screening.</gtr:description><gtr:id>51CB4401-5AC3-430A-921B-8710C3AEF570</gtr:id><gtr:impact>These assays have been used in high-throughput screens carried out at the European Lead Factory to identify new metallo-beta-lactamase inhibitors</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chromo- and fluorigenic assays for beta-lactamases</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Site-selective labeling of target enzymes with 1,1,1-trifluoro-3-bromo acetone (BFA) enables binding events and conformational changes upon ligand binding to be monitored using (19) F NMR spectroscopy.</gtr:description><gtr:id>3ECB7F3D-69BC-405A-8E73-2A45121EE910</gtr:id><gtr:impact>The method has been used to study ligand binding by the NDM-1 (Angew Chem Int Ed Engl. 2014, 53:3129-33) and SPM-1 (Chem Sci. 2015, 6:956-963) metallo-beta-lactamases, establishing that different ligands may utilise different modes of biding to a common target.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Monitoring conformational changes in metallo-?-lactamases by 19F NMR spectroscopy</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Co-ordinates for crystal structures determined under this project. Accession nos.:

4KQO
4KQQ
4KQR

(released entries)

4BP0
4BZ3
4CO9
4C1H
4C1G
4C1F
4C1E
4C1D
4C1C

(unreleased entries; on hold awaiting publication)</gtr:description><gtr:id>AB37B645-1AC7-404F-9ACC-C5DFB873F75C</gtr:id><gtr:impact>Structures are guiding internal SAR within the team.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Crystal structures of beta-lactamases, beta-lactamase:inhibitor complexes and penicillin-binding proteins</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:url>http://www.rcsb.org/pdb</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41F50A87-BE43-40E0-A10E-D35975838F76"><gtr:id>41F50A87-BE43-40E0-A10E-D35975838F76</gtr:id><gtr:title>Genetic and biochemical characterization of an acquired subgroup B3 metallo-?-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a69781a749b82a7b7d9915a511cc033"><gtr:id>5a69781a749b82a7b7d9915a511cc033</gtr:id><gtr:otherNames>Yong D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B083F61-5617-4D16-AEE9-71A9CFECF322"><gtr:id>9B083F61-5617-4D16-AEE9-71A9CFECF322</gtr:id><gtr:title>Crystal Structure of DIM-1, an Acquired Subclass B1 Metallo-?-Lactamase from Pseudomonas stutzeri.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1cca93cf2ef825c718637371c368d0a8"><gtr:id>1cca93cf2ef825c718637371c368d0a8</gtr:id><gtr:otherNames>Booth MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7AE2836-1437-4E90-A498-9A4FE90F1C6E"><gtr:id>B7AE2836-1437-4E90-A498-9A4FE90F1C6E</gtr:id><gtr:title>Arginine-containing peptides as potent inhibitors of VIM-2 metallo-?-lactamase.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18b7f1685084e6e6af82bd936cdeadc3"><gtr:id>18b7f1685084e6e6af82bd936cdeadc3</gtr:id><gtr:otherNames>Rotondo CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F720B38-FDB8-459E-B231-146581F89BE0"><gtr:id>9F720B38-FDB8-459E-B231-146581F89BE0</gtr:id><gtr:title>Role of Residues W228 and Y233 in the Structure and Activity of Metallo-?-Lactamase GIM-1.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35c9e9a35055baf8c7ccac55c300e41a"><gtr:id>35c9e9a35055baf8c7ccac55c300e41a</gtr:id><gtr:otherNames>Skagseth S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6949AF5-4349-433F-AA9E-06D02F45F49A"><gtr:id>D6949AF5-4349-433F-AA9E-06D02F45F49A</gtr:id><gtr:title>Crystal structure of human persulfide dioxygenase: structural basis of ethylmalonic encephalopathy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86712f9fb0070e64384fecb0b342c6d0"><gtr:id>86712f9fb0070e64384fecb0b342c6d0</gtr:id><gtr:otherNames>Pettinati I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD746A2B-8572-4F36-9D8C-EC35A9DEBDA1"><gtr:id>AD746A2B-8572-4F36-9D8C-EC35A9DEBDA1</gtr:id><gtr:title>Structural basis of metallo-?-lactamase, serine-?-lactamase and penicillin-binding protein inhibition by cyclic boronates.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8fc6e433fe4344a56986e08aa6c60e44"><gtr:id>8fc6e433fe4344a56986e08aa6c60e44</gtr:id><gtr:otherNames>Brem J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2EF65FCC-8684-4480-A8E2-9B77DA720D12"><gtr:id>2EF65FCC-8684-4480-A8E2-9B77DA720D12</gtr:id><gtr:title>Studying the active-site loop movement of the S&amp;atilde;o Paolo metallo-?-lactamase-1?Electronic supplementary information (ESI) available: Procedures for protein expression and purification, (19)F-labelling, crystallisation, data collection, and structure determination, table of crystallographic data, table of crystallographic parameters and refinement statistics, figures showing binding mode and distances, procedures for mass s</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8fc6e433fe4344a56986e08aa6c60e44"><gtr:id>8fc6e433fe4344a56986e08aa6c60e44</gtr:id><gtr:otherNames>Brem J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A899005C-28CA-4CA4-A6F9-D17C4723241A"><gtr:id>A899005C-28CA-4CA4-A6F9-D17C4723241A</gtr:id><gtr:title>Infection by and dissemination of NDM-5-producing Escherichia coli in China.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EBD5C19B-CDC5-47CD-85FA-54F36E591D29"><gtr:id>EBD5C19B-CDC5-47CD-85FA-54F36E591D29</gtr:id><gtr:title>QM/MM simulations as an assay for carbapenemase activity in class A ?-lactamases.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89c5f635bc37f4387335cd425afa7aa8"><gtr:id>89c5f635bc37f4387335cd425afa7aa8</gtr:id><gtr:otherNames>Chudyk EI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96AAE45B-B3E9-4C75-93A6-D2009B5973EA"><gtr:id>96AAE45B-B3E9-4C75-93A6-D2009B5973EA</gtr:id><gtr:title>NDM-1 polymicrobial infections including Vibrio cholerae.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f066f68be14b0d6eda1dc5703bd97ecb"><gtr:id>f066f68be14b0d6eda1dc5703bd97ecb</gtr:id><gtr:otherNames>Darley E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/391CA2F1-ED5A-4748-B44E-9D493785025E"><gtr:id>391CA2F1-ED5A-4748-B44E-9D493785025E</gtr:id><gtr:title>Genetic and biochemical characterization of a novel metallo-?-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bda40cd69751b3efdfccfa8ab1e81e54"><gtr:id>bda40cd69751b3efdfccfa8ab1e81e54</gtr:id><gtr:otherNames>El Salabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/922E1AF8-CE36-4A7B-8414-333903BC859D"><gtr:id>922E1AF8-CE36-4A7B-8414-333903BC859D</gtr:id><gtr:title>Extensively drug-resistant New Delhi metallo-?-lactamase-encoding bacteria in the environment, Dhaka, Bangladesh, 2012.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de8b886b99ed0ef6566680bce66b5311"><gtr:id>de8b886b99ed0ef6566680bce66b5311</gtr:id><gtr:otherNames>Toleman MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D4F21BA-990C-4F30-ACBF-F641FCE22178"><gtr:id>7D4F21BA-990C-4F30-ACBF-F641FCE22178</gtr:id><gtr:title>Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/513077402084ceab00f811e53a7f4d2e"><gtr:id>513077402084ceab00f811e53a7f4d2e</gtr:id><gtr:otherNames>Edelstein MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB29B62B-D2B5-4E1D-8F84-BC072CD36C4E"><gtr:id>DB29B62B-D2B5-4E1D-8F84-BC072CD36C4E</gtr:id><gtr:title>Cross-class metallo-?-lactamase inhibition by bisthiazolidines reveals multiple binding modes.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/befc58d95b309466ced570b65ae0e450"><gtr:id>befc58d95b309466ced570b65ae0e450</gtr:id><gtr:otherNames>Hinchliffe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66B34286-31D4-437B-A804-5574BA4DB040"><gtr:id>66B34286-31D4-437B-A804-5574BA4DB040</gtr:id><gtr:title>Prevalence and clinical burden of NDM-1 positive infections in pediatric and neonatal patients in Pakistan.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9989312296d376311a0ba753a755cb5d"><gtr:id>9989312296d376311a0ba753a755cb5d</gtr:id><gtr:otherNames>Qamar MU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0777447C-FA91-40A3-A564-09A53F593EC1"><gtr:id>0777447C-FA91-40A3-A564-09A53F593EC1</gtr:id><gtr:title>Characterization of plasmids in extensively drug-resistant acinetobacter strains isolated in India and Pakistan.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c806eb2ac1c971faf30211a984a2386"><gtr:id>5c806eb2ac1c971faf30211a984a2386</gtr:id><gtr:otherNames>Jones LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA9AE7B7-A029-4C8B-BF9A-763854FBB248"><gtr:id>AA9AE7B7-A029-4C8B-BF9A-763854FBB248</gtr:id><gtr:title>Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b72160ac65d12bcb8a482e1dc0cc9f42"><gtr:id>b72160ac65d12bcb8a482e1dc0cc9f42</gtr:id><gtr:otherNames>Giske CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7730552B-C652-4EA5-BB2B-6A10E04096B0"><gtr:id>7730552B-C652-4EA5-BB2B-6A10E04096B0</gtr:id><gtr:title>Structural and Biochemical Characterization of Rm3, a Subclass B3 Metallo-?-Lactamase Identified from a Functional Metagenomic Study.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/efa19b74bcd8e6ddb3c47b9529ff96ee"><gtr:id>efa19b74bcd8e6ddb3c47b9529ff96ee</gtr:id><gtr:otherNames>Salimraj R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB752F59-DFA0-48D8-B7BB-8314B451C9FF"><gtr:id>DB752F59-DFA0-48D8-B7BB-8314B451C9FF</gtr:id><gtr:title>The road to avibactam: the first clinically useful non-?-lactam working somewhat like a ?-lactam.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3208f709bc1abed42116c259aef6b15"><gtr:id>e3208f709bc1abed42116c259aef6b15</gtr:id><gtr:otherNames>Wang DY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C901E587-E12A-4C46-B554-C2F6E4693295"><gtr:id>C901E587-E12A-4C46-B554-C2F6E4693295</gtr:id><gtr:title>Aspergillomarasmine A overcomes metallo-?-lactamase antibiotic resistance.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7695d55f9bdb24ed909a11353a7fcfdb"><gtr:id>7695d55f9bdb24ed909a11353a7fcfdb</gtr:id><gtr:otherNames>King AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAC74F5E-A460-4BBF-A35F-19D2EEC81173"><gtr:id>EAC74F5E-A460-4BBF-A35F-19D2EEC81173</gtr:id><gtr:title>Global dissemination of a multidrug resistant Escherichia coli clone.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d095648777e022e094ef02e28ed513ca"><gtr:id>d095648777e022e094ef02e28ed513ca</gtr:id><gtr:otherNames>Petty NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA8341E7-42F4-40CB-AFF7-EBB8EDB8D61A"><gtr:id>DA8341E7-42F4-40CB-AFF7-EBB8EDB8D61A</gtr:id><gtr:title>Cyclic Boronates Inhibit All Classes of ?-Lactamase.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5d8773a9ecee2c487a07769f26fb09e"><gtr:id>e5d8773a9ecee2c487a07769f26fb09e</gtr:id><gtr:otherNames>Cahill ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/48B3A9F7-1531-4015-AAB1-B69AD6ACD257"><gtr:id>48B3A9F7-1531-4015-AAB1-B69AD6ACD257</gtr:id><gtr:title>Extended spectrum ?-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria.</gtr:title><gtr:parentPublicationTitle>Critical reviews in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bda40cd69751b3efdfccfa8ab1e81e54"><gtr:id>bda40cd69751b3efdfccfa8ab1e81e54</gtr:id><gtr:otherNames>El Salabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-841X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC385DCA-81D5-4798-A740-BD9F8E99B784"><gtr:id>FC385DCA-81D5-4798-A740-BD9F8E99B784</gtr:id><gtr:title>Monitoring conformational changes in the NDM-1 metallo-?-lactamase by 19F NMR spectroscopy.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ecdd0d06b6e71c2082dd583347dda4d"><gtr:id>7ecdd0d06b6e71c2082dd583347dda4d</gtr:id><gtr:otherNames>Rydzik AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7562539F-1EB7-4A11-947C-E792188C46DE"><gtr:id>7562539F-1EB7-4A11-947C-E792188C46DE</gtr:id><gtr:title>(19) F-NMR Reveals the Role of Mobile Loops in Product and Inhibitor Binding by the S&amp;atilde;o Paulo Metallo-?-Lactamase.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6de25d97265faf8f908a2a6c9c11892a"><gtr:id>6de25d97265faf8f908a2a6c9c11892a</gtr:id><gtr:otherNames>Abboud MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/670B8C25-4510-4664-A797-4EBD3E54FF16"><gtr:id>670B8C25-4510-4664-A797-4EBD3E54FF16</gtr:id><gtr:title>Comparison of Verona Integron-Borne Metallo-?-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/874d6309298a92bbf46070c0982fd4e9"><gtr:id>874d6309298a92bbf46070c0982fd4e9</gtr:id><gtr:otherNames>Makena A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5752906A-9E5A-4A77-ACF2-31CCB866D671"><gtr:id>5752906A-9E5A-4A77-ACF2-31CCB866D671</gtr:id><gtr:title>Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase.</gtr:title><gtr:parentPublicationTitle>ACS infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1177b3dfe60749aa477d86ef14bbe850"><gtr:id>1177b3dfe60749aa477d86ef14bbe850</gtr:id><gtr:otherNames>Gonz?lez MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2373-8227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1641058C-DBD5-4D7B-9077-FC68D8816E28"><gtr:id>1641058C-DBD5-4D7B-9077-FC68D8816E28</gtr:id><gtr:title>Assay platform for clinically relevant metallo-?-lactamases.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0dfdfe9fc54a5d25ec63c34b1d17a7bb"><gtr:id>0dfdfe9fc54a5d25ec63c34b1d17a7bb</gtr:id><gtr:otherNames>van Berkel SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/401D728D-9857-4A25-97B5-E1195BF495ED"><gtr:id>401D728D-9857-4A25-97B5-E1195BF495ED</gtr:id><gtr:title>Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-?-lactamases.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2d0a3f5b1473afddc1c3bebca40b09d0"><gtr:id>2d0a3f5b1473afddc1c3bebca40b09d0</gtr:id><gtr:otherNames>Mojica MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87866CA9-9D48-4C73-9394-AFE942F34800"><gtr:id>87866CA9-9D48-4C73-9394-AFE942F34800</gtr:id><gtr:title>The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/853dbcf060a4d5e5af4ff762f6e6d884"><gtr:id>853dbcf060a4d5e5af4ff762f6e6d884</gtr:id><gtr:otherNames>Walsh TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D11BFFAA-8572-4E8B-B408-DBDE0A90F343"><gtr:id>D11BFFAA-8572-4E8B-B408-DBDE0A90F343</gtr:id><gtr:title>Genetic characterization and emergence of the metallo-?-lactamase GIM-1 in Pseudomonas spp. and Enterobacteriaceae during a long-term outbreak.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0df2c915d37bbd5ff8ea409e71b2a5e9"><gtr:id>0df2c915d37bbd5ff8ea409e71b2a5e9</gtr:id><gtr:otherNames>Wendel AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A33413C-34D4-407D-893F-F84C5E662DEE"><gtr:id>7A33413C-34D4-407D-893F-F84C5E662DEE</gtr:id><gtr:title>Structural Basis of Metallo-?-Lactamase Inhibition by Captopril Stereoisomers.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8fc6e433fe4344a56986e08aa6c60e44"><gtr:id>8fc6e433fe4344a56986e08aa6c60e44</gtr:id><gtr:otherNames>Brem J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1326CC3F-0230-418C-9E87-D73F08732361"><gtr:id>1326CC3F-0230-418C-9E87-D73F08732361</gtr:id><gtr:title>Ejection of structural zinc leads to inhibition of ?-butyrobetaine hydroxylase.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ecdd0d06b6e71c2082dd583347dda4d"><gtr:id>7ecdd0d06b6e71c2082dd583347dda4d</gtr:id><gtr:otherNames>Rydzik AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFEFDA63-F375-4B2A-AC65-ACD28E943611"><gtr:id>DFEFDA63-F375-4B2A-AC65-ACD28E943611</gtr:id><gtr:title>Plasmid carriage of bla NDM-1 in clinical Acinetobacter baumannii isolates from India.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c806eb2ac1c971faf30211a984a2386"><gtr:id>5c806eb2ac1c971faf30211a984a2386</gtr:id><gtr:otherNames>Jones LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C95D3A52-06BC-4433-A55A-57D9BD785CC0"><gtr:id>C95D3A52-06BC-4433-A55A-57D9BD785CC0</gtr:id><gtr:title>Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cc84a1c687636ef1ccc397f8ec22f5b"><gtr:id>5cc84a1c687636ef1ccc397f8ec22f5b</gtr:id><gtr:otherNames>Zowawi HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0D9D6F1-D7C8-47BF-ADD7-5E79A0C32806"><gtr:id>E0D9D6F1-D7C8-47BF-ADD7-5E79A0C32806</gtr:id><gtr:title>Assay for drug discovery: Synthesis and testing of nitrocefin analogues for use as ?-lactamase substrates.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b8d0142c9c363937a1ffeb5dfeb6a44"><gtr:id>6b8d0142c9c363937a1ffeb5dfeb6a44</gtr:id><gtr:otherNames>Ghavami A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA6F8C8D-F169-4A45-8AF2-71775E155BB8"><gtr:id>AA6F8C8D-F169-4A45-8AF2-71775E155BB8</gtr:id><gtr:title>?-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cc84a1c687636ef1ccc397f8ec22f5b"><gtr:id>5cc84a1c687636ef1ccc397f8ec22f5b</gtr:id><gtr:otherNames>Zowawi HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-8512</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/821256F7-C2B0-4EB6-9FC4-2A0D83886C12"><gtr:id>821256F7-C2B0-4EB6-9FC4-2A0D83886C12</gtr:id><gtr:title>Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates in the Gulf Cooperation Council States: dominance of OXA-23-type producers.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5cc84a1c687636ef1ccc397f8ec22f5b"><gtr:id>5cc84a1c687636ef1ccc397f8ec22f5b</gtr:id><gtr:otherNames>Zowawi HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF0F1259-27F7-4BD0-8910-50AE57753B75"><gtr:id>AF0F1259-27F7-4BD0-8910-50AE57753B75</gtr:id><gtr:title>Crystal structure of the mobile metallo-?-lactamase AIM-1 from Pseudomonas aeruginosa: insights into antibiotic binding and the role of Gln157.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/329b1d65cb43a81c64032e99734ef982"><gtr:id>329b1d65cb43a81c64032e99734ef982</gtr:id><gtr:otherNames>Leiros HK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9A4E5B1-19A3-4A1D-BC9D-D7B7588DD3B8"><gtr:id>C9A4E5B1-19A3-4A1D-BC9D-D7B7588DD3B8</gtr:id><gtr:title>The Chemical Biology of Human Metallo-?-Lactamase Fold Proteins.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86712f9fb0070e64384fecb0b342c6d0"><gtr:id>86712f9fb0070e64384fecb0b342c6d0</gtr:id><gtr:otherNames>Pettinati I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9910A06-AE7F-42BA-BD2C-37487CAF669C"><gtr:id>D9910A06-AE7F-42BA-BD2C-37487CAF669C</gtr:id><gtr:title>Drug discovery: spread the risk of antibiotic research.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d08dbf96f1b4fc37e18cb93a58575385"><gtr:id>d08dbf96f1b4fc37e18cb93a58575385</gtr:id><gtr:otherNames>Schofield C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7345C5D-33C5-42C9-AC9E-402FE4C6CE7E"><gtr:id>D7345C5D-33C5-42C9-AC9E-402FE4C6CE7E</gtr:id><gtr:title>Biochemical characterization of New Delhi metallo-?-lactamase variants reveals differences in protein stability.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/874d6309298a92bbf46070c0982fd4e9"><gtr:id>874d6309298a92bbf46070c0982fd4e9</gtr:id><gtr:otherNames>Makena A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/60D772B6-45DB-4FAC-B4E8-E91AF9BA79DF"><gtr:id>60D772B6-45DB-4FAC-B4E8-E91AF9BA79DF</gtr:id><gtr:title>Chromophore-linked substrate (CLS405): probing metallo-?-lactamase activity and inhibition.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/874d6309298a92bbf46070c0982fd4e9"><gtr:id>874d6309298a92bbf46070c0982fd4e9</gtr:id><gtr:otherNames>Makena A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B7135E7-DEA7-44CA-BA3F-63A4DC47076F"><gtr:id>7B7135E7-DEA7-44CA-BA3F-63A4DC47076F</gtr:id><gtr:title>Applications of structure-based design to antibacterial drug discovery.</gtr:title><gtr:parentPublicationTitle>Bioorganic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d314de7e3626dbce1f668b0f4928248e"><gtr:id>d314de7e3626dbce1f668b0f4928248e</gtr:id><gtr:otherNames>Cain R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0045-2068</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA3EB7C6-ADAF-4D36-9D10-FC8091F70E33"><gtr:id>FA3EB7C6-ADAF-4D36-9D10-FC8091F70E33</gtr:id><gtr:title>Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A84EBD1-4EA8-48CD-874C-0350127255B4"><gtr:id>8A84EBD1-4EA8-48CD-874C-0350127255B4</gtr:id><gtr:title>Binding of (5S)-penicilloic acid to penicillin binding protein 3.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0dfdfe9fc54a5d25ec63c34b1d17a7bb"><gtr:id>0dfdfe9fc54a5d25ec63c34b1d17a7bb</gtr:id><gtr:otherNames>van Berkel SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21CFD33E-E8A9-42DB-8F6D-8A702F70C752"><gtr:id>21CFD33E-E8A9-42DB-8F6D-8A702F70C752</gtr:id><gtr:title>Rhodanine hydrolysis leads to potent thioenolate mediated metallo-?-lactamase inhibition.</gtr:title><gtr:parentPublicationTitle>Nature chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8fc6e433fe4344a56986e08aa6c60e44"><gtr:id>8fc6e433fe4344a56986e08aa6c60e44</gtr:id><gtr:otherNames>Brem J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1755-4330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23FC99A1-F7E8-4F14-A44F-3C5F4D10809B"><gtr:id>23FC99A1-F7E8-4F14-A44F-3C5F4D10809B</gtr:id><gtr:title>blaNDM-1 is a chimera likely constructed in Acinetobacter baumannii.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de8b886b99ed0ef6566680bce66b5311"><gtr:id>de8b886b99ed0ef6566680bce66b5311</gtr:id><gtr:otherNames>Toleman MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7B91DF3-044F-403A-A950-8B86EA56BD6B"><gtr:id>A7B91DF3-044F-403A-A950-8B86EA56BD6B</gtr:id><gtr:title>Crystal structures of Pseudomonas aeruginosa GIM-1: active-site plasticity in metallo-?-lactamases.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7bdfe2668bb561d509b89582e3d6f771"><gtr:id>7bdfe2668bb561d509b89582e3d6f771</gtr:id><gtr:otherNames>Borra PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9E666082-8D5C-4E72-B6AE-CCEAC5ED8FF5"><gtr:id>9E666082-8D5C-4E72-B6AE-CCEAC5ED8FF5</gtr:id><gtr:title>Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2107490ba1ae5f5dd21b0c1d4add91ca"><gtr:id>2107490ba1ae5f5dd21b0c1d4add91ca</gtr:id><gtr:otherNames>Calvopi?a K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100135</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>